Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01159652 · ClinicalTrials.gov registry record · Phase 4

Hypnotic Medications and Memory: Effect of Drug Exposure During the Night

A Phase 4 study of Sleep and Memory, sponsored by St. Luke's Hospital, Chesterfield, Missouri.

Completed
Registry status
Phase 4
Development phase
26
Enrollment target
1
Study location

NCT01159652 is a Phase 4 study of Sleep and Memory that has completed, run by St. Luke's Hospital, Chesterfield, Missouri. The registered enrollment target is 26 participants, below the 4,166-participant average among 151 other Sleep trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01159652, a Phase 4 study of Sleep and Memory, has completed, sponsored by St. Luke's Hospital, Chesterfield, Missouri.

COMPLETED
Registry status
Phase 4
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect of two hypnotic medications, zolpidem extended release and zaleplon, on memory. It is expected that a hypnotic with shorter drug duration will allow greater memory consolidation than a hypnotic with longer drug duration.

Conditions Studied

Interventions

  • DRUG zaleplon
  • DRUG zolpidem extended release
  • DRUG bedtime placebo
  • DRUG middle of the night placebo

Study Locations (1)

Missouri

  • St. Luke's Hospital Sleep Medicine and Research Center - Chesterfield

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2010-10
Est. Completion 2011-05
Phase Phase 4

What the Registry Record Tells You About NCT01159652

The ClinicalTrials.gov registry entry for NCT01159652 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,166-participant average among 151 other Sleep trials with a reported enrollment target (99% lower). The listed sponsor is St. Luke's Hospital, Chesterfield, Missouri, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sleep appearing as the primary indexed condition, and to 4 interventions - of which zaleplon is the first listed.

NCT01159652 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT01159652 about?

NCT01159652 is a clinical study titled "Hypnotic Medications and Memory: Effect of Drug Exposure During the Night". The purpose of this study is to determine the effect of two hypnotic medications, zolpidem extended release and zaleplon, on memory. It is expected that a hypnotic with shorter drug duration will allow greater memory consolidation than a hypnotic with longer drug duration.

What is the current status of trial NCT01159652?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2010-10. Estimated completion is 2011-05.

What conditions does trial NCT01159652 study?

This clinical trial studies the following conditions: Sleep, Memory.

What interventions are being tested in trial NCT01159652?

The interventions under investigation include: zaleplon (DRUG), zolpidem extended release (DRUG), bedtime placebo (DRUG), middle of the night placebo (DRUG).

Who is sponsoring clinical trial NCT01159652?

This trial is sponsored by St. Luke's Hospital, Chesterfield, Missouri, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01159652 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.